Cited by 354Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesSphingolipid Metabolism and Signaling

The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Open access

Cox, Adrienne D., Der, Channing J., Philips, Mark R.·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-3214PMC PMC4400837

Open this paper in CoChat — free account

Abstract

RAS proteins require membrane association for their biologic activity, making this association a logical target for anti-RAS therapeutics. Lipid modification of RAS proteins by a farnesyl isoprenoid is an obligate step in that association, and is an enzymatic process. Accordingly, farnesyltransferase inhibitors (FTI) were developed as potential anti-RAS drugs. The lack of efficacy of FTIs as anticancer drugs was widely seen as indicating that blocking RAS membrane association was a flawed approach to cancer treatment. However, a deeper understanding of RAS modification and trafficking has revealed that this was an erroneous conclusion. In the presence of FTIs, KRAS and NRAS, which are the RAS isoforms most frequently mutated in cancer, become substrates for alternative modification, can still associate with membranes, and can still function. Thus, FTIs failed not because blocking RAS membrane association is an ineffective approach, but because FTIs failed to accomplish that task. Recent findings regarding RAS isoform trafficking and the regulation of RAS subcellular localization have rekindled interest in efforts to target these processes. In particular, improved understanding of the palmitoylation/depalmitoylation cycle that regulates RAS interaction with the plasma membrane, endomembranes, and cytosol, and of the potential importance of RAS chaperones, have led to new approaches. Efforts to validate and target other enzymatically regulated posttranslational modifications are also ongoing. In this review, we revisit lessons learned, describe the current state of the art, and highlight challenging but promising directions to achieve the goal of disrupting RAS membrane association and subcellular localization for anti-RAS drug development. Clin Cancer Res; 21(8); 1819–27. ©2015 AACR. See all articles in this CCR Focus section, “Targeting RAS-Driven Cancers.”

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-3214

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“The three RAS genes (HRAS, NRAS, KRAS) are the most commonly mutated oncogenes in human cancers (1,2).”
Background
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citation
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,042
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
An Acylation Cycle Regulates Localization and Activity of Palmitoylated Ras Isoforms
Rocks, O., Peyker, A., Kahms, M., Verveer, P., Koerner, C., Lumbierres, M., Kuhlmann, J., Waldmann, H., Wittinghofer, A., & Bastiaens, P. (2005) · Science · doi:10.1126/science.1105654 · Cited by 866
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Self-citation
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 3×
“Such inhibitors have been developed and some have reached the clinic (16,17), but have been limited by toxicity (21-23).”
Background
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596

Show all 105 references

Sorted by citations

Items 101–200 of 354

The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure
Zhou, Y., Prakash, P., Hong, L., Gorfe, A. A., & Hancock, J. F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014605118 · Cited by 46
The role of S‐acylation in protein trafficking
Daniotti, J. L., Pedro, M. P., & Taubas, J. V. (2017) · Traffic · doi:10.1111/tra.12510 · Cited by 46
Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Klochkov, S. G., Евгеньевна, Н. М., Yarla, N. S., Parvathaneni, M., Sharma, B., Tarasov, V. V., Barreto, G. E., Бачурин, С. О., Ashraf, G. M., & Aliev, G. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.010 · Cited by 46
The role of KRAS splice variants in cancer biology
Nuevo‐Tapioles, C., & Philips, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1033348 · Cited by 48
Self-citation
Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases
Gentry, L. R., Nishimura, A., Cox, A. D., Martin, T. D., Tsygankov, D., Nishida, M., Elston, T. C., & Der, C. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.656710 · Cited by 45
Self-citation
Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms
Nakhaei‐Rad, S., Haghighi, F., Nouri, P., Adariani, S. R., Lissy, J., Jasemi, N. S. K., Dvorský, R., & Ahmadian, M. R. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1431605 · Cited by 44
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
Passiglia, F., Malapelle, U., Re, M. D., Righi, L., Pagni, F., Furlan, D., Danesi, R., Troncone, G., & Novello, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.023 · Cited by 43
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion
Choi, B. H., Philips, M. R., Chen, Y., Lu, L., & Dai, W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003723 · Cited by 42
Self-citation
The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding
Banerjee, A., Jang, H., Nussinov, R., & Gaponenko, V. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.11.010 · Cited by 42
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M. R., Greenstein, A. E., & Townsend, J. P. (2018) · Oncogene · doi:10.1038/s41388-017-0105-z · Cited by 43
Self-citation
Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations
Burge, R. A., & Hobbs, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.004 · Cited by 44
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Brock, E. J., Ji, K., Reiners, J. J., & Mattingly, R. R. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001154002 · Cited by 41
The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease
Zhao, Y., Wu, T., Zhao, M., & Li, C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.008897 · Cited by 42
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Vichas, A., Riley, A. K., Nkinsi, N. T., Kamlapurkar, S., Parrish, P. C. R., Lo, A., Duke, F. F., Chen, J., Fung, I., Watson, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24841-y · Cited by 43
USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer
Maier, C. R., Hartmann, O., Prieto‐Garcia, C., Al-Shami, K. M., Schlicker, L., Vogel, F. C. E., Haid, S., Klann, K., Buck, V., Münch, C., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01173-6 · Cited by 40
Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome
Yavuz, B. R., Arici, M. K., Demirel, H. C., Tsai, C., Jang, H., Nussinov, R., & Tunçbağ, N. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00377-6 · Cited by 41
Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids
Senkowski, W., Jarvius, M., Rubin, J., Lengqvist, J., Gustafsson, M. G., Nygren, P., Kultima, K., Larsson, R. L., & Fryknäs, M. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.09.013 · Cited by 41
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, C., Li, Y., Li, L.-L., Fan, X.-X., Wang, Y.-W., Wei, C.-L., Liu, L., Leung, E. L.-H., & Yao, X.-J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00823 · Cited by 40
Palmitoylation of the KATP channel Kir6.2 subunit promotes channel opening by regulating PIP2 sensitivity
Yang, H.-Q., Martinez-Ortiz, W., Hwang, J., Fan, X., Cardozo, T., & Coetzee, W. (2020) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1918088117 · Cited by 34
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
Vanni, I., Tanda, E. T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W., Boutros, A., Spagnolo, F., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00172 · Cited by 43
Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling
Adams, L. M., DeHart, C. J., Drown, B., Anderson, L. C., Bocik, W., Boja, E. S., Hiltke, T., Hendrickson, C. L., Rodriguez, H., Caldwell, M. A., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102768 · Cited by 37
New prospectives on treatment opportunities in RASopathies
Gelb, B. D., Yohe, M. E., Wolf, C. M., & Andelfinger, G. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32024 · Cited by 39
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodríguez, F. J., Gross, J. M., Allen, A. N., Wan, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02305-x · Cited by 38
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 40
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
Dietrich, P., Freese, K., Mahli, A., Thasler, W. E., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncotarget · doi:10.18632/oncotarget.23188 · Cited by 36
The Genomic Landscape of Melanoma and Its Therapeutic Implications
Yang, T., Yu, S., Ke, C. K., & Cheng, S. (2023) · Genes · doi:10.3390/genes14051021 · Cited by 36
Correlated S -palmitoylation profiling of Snail-induced epithelial to mesenchymal transition
Hernandez, J. L., Davda, D., Majmudar, J. D., Won, S. J., Prakash, A., Choi, A. I., & Martin, B. R. (2016) · Molecular BioSystems · doi:10.1039/c6mb00019c · Cited by 34
The Nogo-B receptor promotes Ras plasma membrane localization and activation
Zhao, B., Hu, W., Kumar, S. N., Gonyo, P., Rana, U., Liu, Z., Wang, B., Duong, W. Q., Yang, Z., Williams, C. L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.484 · Cited by 34
RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention
Van, Q. N., Prakash, P., Shrestha, R., Balius, T. E., Turbyville, T. J., & Stephen, A. G. (2021) · Biomolecules · doi:10.3390/biom11030377 · Cited by 34
Ras sumoylation in cell signaling and transformation
Dai, W., Xie, S., Chen, C., & Choi, B. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.033 · Cited by 27
Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation
Lee, K. H., Koh, M., & Moon, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.4837 · Cited by 33
Antiviral therapy of hepatitis delta virus infection — progress and challenges towards cure
Wranke, A., & Wedemeyer, H. H. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.10.002 · Cited by 33
KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Karimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 37
Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics
Smigiel, J. M., Parameswaran, N., & Jackson, M. W. (2018) · Cancers · doi:10.3390/cancers10010014 · Cited by 31
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
Žúbor, P., Daňková, Z., Kolková, Z., Holubeková, V., Braný, D., Meršaková, S., Samec, M., Líšková, A., Koklesová, L., Kubatka, P., et al. (2020) · Cancers · doi:10.3390/cancers12051292 · Cited by 32
Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30
K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 30
Mechanism of activation and the rewired network: New drug design concepts
Nussinov, R., Zhang, M., Maloney, R., Tsai, C., Yavuz, B. R., Tunçbağ, N., & Jang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21863 · Cited by 30
PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization
Muratcioğlu, S., Jang, H., Gürsoy, A., Keskin, Ö., & Nussinov, R. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b03035 · Cited by 30
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Zhao, H., Liu, P., Zhang, R., Wu, M. H., Li, D., Zhao, X., Zhang, C., Jiao, B., Chen, B., Chen, Z., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0226-1 · Cited by 30
Inhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 29
Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling
Seshacharyulu, P., Halder, S., Nimmakayala, R. K., Rachagani, S., Chaudhary, S., Atri, P., Chirravuri‐Venkata, R., Ouellette, M. M., Carmicheal, J., Gautam, S. K., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103772 · Cited by 30
The renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 30
Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation
Agabiti, S. S., Li, J., & Wiemer, A. J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.101 · Cited by 28
KRAS regulation by small non-coding RNAs and SNARE proteins
Che, Y., Siprashvili, Z., Kovalski, J. R., Jiang, T., Wozniak, G. G., Elcavage, L. E., & Khavari, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13106-4 · Cited by 30
From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
Saliani, M., Jalal, R., & Ahmadian, M. R. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0530 · Cited by 27
Palmitoylation as a Signal for Delivery
Wang, Y., Lu, H., Fang, C., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_16 · Cited by 28
The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology
Dracopoli, N. C., & Boguski, M. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.007 · Cited by 26
Small GTPase peripheral binding to membranes: molecular determinants and supramolecular organization
Peurois, F., Peyroche, G., & Cherfils, J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170525 · Cited by 27
A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting
Shu, L., Wang, D., Saba, N. F., & Chen, Z. G. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0660 · Cited by 27
Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety
Grant, B., Enomoto, M., Back, S.-I., Lee, K., Gebregiworgis, T., Ishiyama, N., Ikura, M., & Marshall, C. B. (2020) · Science Signaling · doi:10.1126/scisignal.aaz0344 · Cited by 27
PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
Huang, Z., Liu, M., Li, D., Tan, Y., Zhang, R., Xia, Z., Wang, P., Jiao, B., Liu, P., & Ren, R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011060 · Cited by 27
Understand KRAS and the Quest for Anti-Cancer Drugs
Han, C. W., Jeong, M. S., & Jang, S. B. (2021) · Cells · doi:10.3390/cells10040842 · Cited by 27
Lipid Profiles of RAS Nanoclusters Regulate RAS Function
Zhou, Y., & Hancock, J. F. (2021) · Biomolecules · doi:10.3390/biom11101439 · Cited by 26
RAS nanoclusters are cell surface transducers that convert extracellular stimuli to intracellular signalling
Zhou, Y., & Hancock, J. F. (2023) · FEBS Letters · doi:10.1002/1873-3468.14569 · Cited by 27
The G protein–coupled receptor GPR31 promotes membrane association of KRAS
Fehrenbacher, N., da Silva, I. T., Ramírez, C., Zhou, Y., Cho, K.-J., Kuchay, S., Shi, J., Thomas, S., Pagano, M., Hancock, J. F., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201609096 · Cited by 26
Self-citation
LvRas and LvRap are both important for WSSV replication in Litopenaeus vannamei
Tseng, Y.-T., Kumar, R., & Wang, H. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.02.035 · Cited by 27
Therapeutic targeting of protein S-acylation for the treatment of disease
Fraser, N. J., Howie, J., Wypijewski, K. J., & Fuller, W. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190707 · Cited by 29
Scratching the surface: native mass spectrometry of peripheral membrane protein complexes
Sahin, C., Reid, D. J., Marty, M. T., & Landreh, M. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190787 · Cited by 29
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 27
Direct Modulators of K-Ras–Membrane Interactions
Morstein, J., Shrestha, R., Van, Q. N., López, C. A., Arora, N., Tonelli, M., Hong, L., Chen, D., Zhou, Y., Hancock, J. F., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00413 · Cited by 27
Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans
Bessler, W., Hudson, F. Z., Zhang, H., Harris, V. K., Wang, Y., Mund, J. A., Downing, B., Ingram, D. A., Case, J., Fulton, D. J., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.06.002 · Cited by 26
H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences
Drosten, M., Simón-Carrasco, L., Hernández-Porras, I., Lechuga, C. G., Blasco, M. T., Jacob, H. K. C., Fabbiano, S., Potenza, N., Bustelo, X. R., Guerra, C. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2925 · Cited by 26
A Novel α/β Hydrolase Domain Protein Derived From Haemonchus contortus Acts at the Parasite-Host Interface
Lu, M., Tian, X., Tian, A.-L., Li, Z., Yan, R., Xu, L., Song, X., & Li, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01388 · Cited by 25
Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins
Zhang, Y., Wang, Z., Ma, X., Yang, S., Hu, X., Tao, J., Hou, Y., & Bai, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.002 · Cited by 25
Small molecule inhibitors of RAS proteins with oncogenic mutations
Orgován, Z., & Keserű, G. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09911-9 · Cited by 25
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
Coley, A. B., Ward, A., Keeton, A. B., Chen, X., Maxuitenko, Y. Y., Prakash, A., Li, F., Foote, J. B., Buchsbaum, D. J., & Piazza, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.009 · Cited by 23
Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins
Buchou, C., Laud-Duval, K., van der Ent, W., Grossetête, S., Zaïdi, S., Gentric, G., Corbé, M., Müller, K., Nery, E. D., Surdez, D., et al. (2022) · Cancers · doi:10.3390/cancers14092327 · Cited by 26
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 25
Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation
Agabiti, S. S., Liang, Y., & Wiemer, A. J. (2016) · Molecular Membrane Biology · doi:10.1080/09687688.2016.1213432 · Cited by 25
Skin Development and Disease: A Molecular Perspective
Dermitzakis, I., Chatzi, D., Kyriakoudi, S. A., Evangelidis, N., Vakirlis, E., Meditskou, S., Theotokis, P., & Μanthou, M. E. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080487 · Cited by 28
Changing the course of pancreatic cancer – Focus on recent translational advances
Javle, M. M., Golan, T., & Maitra, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.004 · Cited by 24
SmgGDS: An Emerging Master Regulator of Prenylation and Trafficking by Small GTPases in the Ras and Rho Families
Brandt, A. C., Koehn, O. J., & Williams, C. L. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.685135 · Cited by 24
A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo
Wang, Z., Yuan, Q., Chen, X., Luo, F., Shi, X., Guo, F., Ren, J., Li, S., & Shang, D. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01158-1 · Cited by 24
An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth
Kaya, P., Schaffner‐Reckinger, E., Manoharan, G. B., Vukić, V., Kiriazis, A., Ledda, M., Renedo, M. B., Pavic, K., Gaigneaux, A., Glaab, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02129 · Cited by 22
Targeting RAS in pediatric cancer: is it becoming a reality?
Vaseva, A. V., & Yohe, M. E. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000856 · Cited by 24
PI3Kγ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition—Moving Towards Cell Specific PI3K Targeting?
Jin, J. R., Gogvadze, E. V., Xavier, A. R., Bohnacker, T., Völzmann, J., & Wymann, M. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585070 · Cited by 22
Emerging role of small GTPases and their interactome in plants to combat abiotic and biotic stress
Ganotra, J., Sharma, B., Biswal, B., Bhardwaj, D., & Tuteja, N. K. (2022) · PROTOPLASMA · doi:10.1007/s00709-022-01830-6 · Cited by 23
Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs
Quah, S. Y., Tan, M. S., Teh, Y. H., & Stanslas, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.010 · Cited by 26
Individual S-acylated cysteines differentially contribute to H-Ras endomembrane trafficking and acylation/deacylation cycles
Pedro, M. P., Vilcaes, A. A., Gomez, G. A., & Daniotti, J. L. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-08-0603 · Cited by 22
The promise of signal transduction in genetically driven sarcomas of the nerve
Kim, A., & Pratilas, C. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.014 · Cited by 22
Regulation of NOTCH signaling by RAB7 and RAB8 requires carboxyl methylation by ICMT
Court, H., Ahearn, I. M., Amoyel, M., Bach, E. A., & Philips, M. R. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201701053 · Cited by 24
Self-citation
Induction of N-Ras degradation by flunarizine-mediated autophagy
Zheng, Z.-Y., Li, J., Li, F., Zhu, Y., Cui, K., Wong, S. T. C., Chang, E. C., & Liao, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-35237-2 · Cited by 23
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma
Lu, H., Zhou, L., Zuo, H., Le, W., Hu, J., Zhang, T., Li, M., & Yuan, Y. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04199-6 · Cited by 22
Multidisciplinary Management of Costello Syndrome: Current Perspectives
Leoni, C., Viscogliosi, G., Tartaglia, M., Aoki, Y., & Zampino, G. (2022) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s291757 · Cited by 21
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21
Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders
Li, Y.-C., Lytle, N. K., Gammon, S. T., Wang, L., Hayes, T. K., Sutton, M. N., Bast, R. C., Der, C. J., Piwnica-Worms, D. R., McCormick, F. P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000848117 · Cited by 20
Self-citation
RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains
Zhou, Y., Gorfe, A. A., & Hancock, J. F. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.686338 · Cited by 21
A brief history of RAS and the RAS Initiative
McCormick, F. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.003 · Cited by 20
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Javaid, S., Schaefer, A., Goodwin, C. M., Nguyen, V. V., Massey, F. L., Pierobon, M., Gambrell-Sanders, D., Waters, A. M., Lambert, K. N., Diehl, J. N., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0142 · Cited by 21
Self-citation
The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv, J., Wang, J., Chang, S., Liu, M., & Pang, X. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv102 · Cited by 22
Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation
Ganesan, L., Shieh, P., Bertozzi, C. R., & Levental, I. (2017) · Scientific Reports · doi:10.1038/srep41147 · Cited by 20
Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers
Nussinov, R., Zhang, M., Tsai, C., & Jang, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.032 · Cited by 21
Protein Isoprenylation in Yeast Targets COOH-Terminal Sequences Not Adhering to the CaaX Consensus
Berger, B. M., Kim, J. H., Hildebrandt, E. R., Davis, I. C., Morgan, M. C., Hougland, J. L., & Schmidt, W. K. (2018) · Genetics · doi:10.1534/genetics.118.301454 · Cited by 20
Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
Lee, J. J., Jain, V., & Amaravadi, R. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212402 · Cited by 20
KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer
Yang, Y., Sang, Z., Ma, J., Zhu, Y., & Wu, S. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2969 · Cited by 19
Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics
Xu, M., & Xu, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02309-7 · Cited by 20
Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives
Tisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 18

Authors: Cox, A. D., Der, C. J., & Philips, M. R.
Affiliations: University of North Carolina at Chapel Hill (US)
NYU Langone Health (US)
ORCID: Cox, Adrienne D.
Der, Channing J.
Philips, Mark R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-04-14
Volume: 21
Issue: 8
Pages: 1819-1827
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-3214
PMC: PMC4400837
OpenAlex: W2129653056
Cited by: 351
References: 105
Citations by year: 2026: 11 · 2025: 15 · 2024: 19 · 2023: 31 · 2022: 30 · 2021: 46 · 2020: 39 · 2019: 29 · 2018: 43 · 2017: 40 · 2016: 28 · 2015: 18
FWCI: 4.17
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
UNC Libraries
Funders: Pancreatic Cancer Action Network
National Institutes of Health (5r01ca042978-30)
National Cancer Institute (R01CA116034, R01CA175747, R01CA163489, R01-CA042978, R21CA179193)
National Institute of General Medical Sciences (R01GM055279)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords: farnesyltransferase inhibitors, KRAS, NRAS, depalmitoylation, post-translational modification, RAS-driven cancers
MeSH terms: Acetyltransferases, Acylation, Animals, Antineoplastic Agents, Carrier Proteins, Cell Membrane, Humans, Neoplasms, Endopeptidases, Phosphorylation, Protein Kinase C, Thiolester Hydrolases, Signal Transduction, Proto-Oncogene Proteins p21(ras), Protein Prenylation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Alkyl and Aryl Transferases, Amino Acid Motifs, Protein Transport, Protein Interaction Domains and Motifs, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks